Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: An Emerging Role for Evolocumab?

J Am Coll Cardiol. 2019 Jun 18;73(23):2971-2975. doi: 10.1016/j.jacc.2019.03.514.

Authors

David Z I Cherney¹, Robert S Rosenson², Patrick R Lawler³

Affiliations

¹ Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada; Department of Physiology and Institute of Medical Sciences, and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. Electronic address: [email protected].
² Department of Cardiovascular Diseases, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, Mount Sinai Heart, New York, New York.
³ Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada; Ted Rogers Centre for Heart Research, and Heart and Stroke/Richard Lewar Centre of Excellence, University of Toronto, Toronto, Ontario, Canada.

PMID: 31196454
DOI: 10.1016/j.jacc.2019.03.514

No abstract available

Keywords: atherosclerotic cardiovascular disease; evolocumab; hyperlipidemia; secondary prevention.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Atherosclerosis*
Cardiovascular Diseases*
Humans
Renal Insufficiency, Chronic*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
evolocumab